Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00985868
Other study ID # CDR0000653387
Secondary ID UKM-ICRF-CR0708-
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2009
Est. completion date November 20, 2019

Study information

Verified date November 2019
Source Cancer Research UK
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: AT9283 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in children and adolescents with relapsed and refractory solid tumors.


Description:

OBJECTIVES:

Primary

- To evaluate the safety and tolerability of Aurora kinase inhibitor AT9283 by characterizing the dose-limiting toxicities in children and adolescents with relapsed and refractory solid tumors.

- To determine the maximum-tolerated dose of this regimen in these patients.

Secondary

- To determine the pharmacokinetic parameters of this regimen in these patients.

- To demonstrate the pharmacodynamic (PD) activity of this regimen in these patients by studying its effects in surrogate tissue.

- To assess preliminary evidence of activity of this regimen by using appropriate objective tumor measurements in these patients.

Tertiary

- To demonstrate the PD activity of this regimen in these patients by studying its effects in both surrogate and tumor tissue (skin punch, bone marrow, and tumor biopsies).

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive Aurora kinase inhibitor AT9283 IV over 72 hours on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.If a patient is benefiting from treatment with AT9283 (i.e. has stable or responding disease as measured by RECIST) and the benefit risk balance is considered acceptable then further treatment may be given.

Blood and skin tissue samples are collected at baseline and periodically during treatment for pharmacokinetic studies and pharmacodynamic and biomarker (M30, M65, pHH53, p53, PCNA and Ki67) analysis by IHC and ELISA assays.

After completion of study therapy, patients are followed up periodically.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date November 20, 2019
Est. primary completion date January 25, 2016
Accepts healthy volunteers No
Gender All
Age group 2 Years to 18 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed solid tumor meeting 1 of the following criteria:

- Refractory to conventional treatment

- Disease for which no conventional therapy exists

- Patients with CNS tumors must be on a stable or decreasing dose of dexamethasone for = 1 week before study entry

PATIENT CHARACTERISTICS:

- WHO performance status (PS) 0-2 OR Lansky Play PS 70-100% (> 50% is acceptable if it is due to a stable neurological deficit or CNS tumor)

- Life expectancy = 12 weeks

- ANC = 1,000/mm^3

- Platelet count = 100,000/mm^3

- Hemoglobin = 9.0 g/dL

- Serum bilirubin < 1.5 times upper limit of normal (ULN)

- Creatinine kinase normal

- ALT or AST < 2.5 times ULN (= 5 times ULN if due to tumor)

- Creatinine clearance/EDTA-measured GFR = 60 mL/min

- Sufficient blood volume to undergo the blood-sampling regimen specified by the protocol that, in the opinion of the investigator, will not jeopardize patient's safety

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and for 6 months after completion of study therapy

- Not at high medical risk because of non-malignant systemic disease, including active uncontrolled infection

- Not known to be serologically positive for hepatitis B or C or HIV

- Fractional shortening of > 29% on echocardiogram

- LVEF = 50%

- No history of allergy or auto-immune disease

- No congenital heart disease

- No other condition that, in the investigator's opinion, would not make the patient a good candidate for the clinical trial

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from prior therapy

- More than 4 weeks since prior radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy, or chemotherapy (6 weeks for investigational medicinal products, 2 weeks for vincristine)

- More than 3 months since prior autologous stem cell transplantation

- No prior allogenic bone marrow transplantation

- No prior extensive radiotherapy to > 25% of bone marrow

- No prior Aurora kinase inhibitor

- No prior major thoracic or abdominal surgery from which the patient has not yet recovered

- No prior or concurrent participation in another interventional clinical trial

- Participation in an observational study allowed

- No other concurrent anticancer therapy or investigational drugs

Study Design


Related Conditions & MeSH terms

  • Neoplasms
  • Unspecified Childhood Solid Tumor, Protocol Specific

Intervention

Drug:
multikinase inhibitor AT9283

Other:
enzyme-linked immunosorbent assay

immunohistochemistry staining method

laboratory biomarker analysis

pharmacological study


Locations

Country Name City State
United Kingdom Birmingham Children's Hospital Birmingham England
United Kingdom Leeds General Infirmary Leeds England
United Kingdom Royal Manchester Children's Hospital Manchester England
United Kingdom Great North Children's Hospital, Royal Victoria Infirmary Newcastle-Upon-Tyne England
United Kingdom Royal Marsden - Surrey Sutton England

Sponsors (1)

Lead Sponsor Collaborator
Cancer Research UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicities
Primary Maximum-tolerated dose
Secondary Pharmacokinetic parameters and the correlation between them and toxicity and/or efficacy
Secondary The magnitude and duration of biomarkers (M30 and M65 ELISA) change after AT9283 administration
Secondary Objective tumor response according to RECIST criteria
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT01164163 - INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Phase 1
Terminated NCT00949117 - Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer Phase 2
Completed NCT00281944 - Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors Phase 1
Completed NCT00253474 - PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Phase 1
Recruiting NCT00084695 - Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Phase 2
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Completed NCT00003070 - Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer Phase 3
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00016861 - Irinotecan in Treating Children With Refractory or Progressive Solid Tumors Phase 1
Completed NCT00003754 - Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers Phase 2
Completed NCT00004005 - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Recruiting NCT00898794 - Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer N/A
Terminated NCT00429702 - Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy Phase 2
Completed NCT00459238 - Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants N/A
Completed NCT00387920 - Sunitinib in Treating Young Patients With Refractory Solid Tumors Phase 1
Completed NCT00138216 - Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase 1
Completed NCT00070473 - Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors Phase 1
Terminated NCT00176540 - Dextromethorphan in Treating Patients With Fatigue Caused by Cancer N/A